May 29, 2024 03:31 PM EDT
Pharma
FDA+

FDA ap­proves Tris Phar­ma's non-stim­u­lant pe­di­atric AD­HD liq­uid med­ica­tion

Lia DeGroot

The FDA ap­proved Tris Phar­ma’s Ony­da XR to treat AD­HD in chil­dren who are at least 6 years old.

It’s the first liq­uid non-stim­u­lant AD­HD …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

A service from the Financial Times